الفهرس 
List of contentOnly 14 pages are availabe for public view
 |  | from | 151 |  |  |
| | | from | 151 | | |
Abstract
Exogenous human chorionic gonadotropin (HCG), in addition to its well-known endocrine effect on the corpus luteum, may act as a growth and differentiation factor during pregnancy. During in vitro fertilization (IVF), it is usually used as a surrogate luteinizing hormone (LH) surge to induce final oocyte maturation. The most common dose of HCG used in IVF is 10.000 IU. HCG is also a prerequisite for the ovarian hyperstimulation syndrome (OHSS) which in its moderate and severe forms can cause significant morbidity and can be fatal in its critical stage.The incidence of severe OHSS is low and in the range of 0.5–2% of all IVF cycles. Currently, there is no agreement on the optimal dose requirements of HCG for final oocyte maturation yet. The first study to address this question demonstrated a significantly lower in oocyte recovery rate in patients who received 2.000 IU of uHCG compared with patients who received either 5.000 or 10.000 IU of uHCG.Studies in non-human primates have shown that HCG dose of 3-10 folds lower than standard dose have been sufficient to reinitiate meiosis of oocytes and induce luteinization of granulose cells. Moreover, many retrospective studies showed that the reduced dose (i.e., 4.000–6.000 IU) could trigger final oocyte maturation without affecting clinical pregnancy rate and may also decrease the moderate or severe OHSS rate.In the current study we aimed to compare the effectiveness of lower dose of uHCG (5.000 IU) to the conventional dose of uHCG (10.000 IU) in completion of final oocyte maturation before retrieval during IVF and ICSI cycles. *This study conducted on 166 cases divided into two groups: - group A were given Injection of 5.000 IU of uHCG to trigger ovulation. - group B were given Injection of 10.000 IU of uHCG to trigger ovulation. * In the current study there were : - Insignificant differences between the two groups as regard age, BMI, duration of infertility, gravidity and parity. - Insignificant difference between the two groups as regard indication for treatment. -Insignificant difference between the two groups as regard hormonal profile. - Significant increase in group B as regard endometrial thickness on the day of HCG. - E2 level on HCG day (pg/mL) was higher in group received reduced doses versus high doses but not reach significance. - Increase in total number of follicles more than 14 mm in group A versus group B and as regard HCG levels after HCG triggering there was significant increase in group B versus group A. - Significant elevation in number of oocytes retrieved and mature oocyte in group A versus group B. - number of available embryos is higher in cases received reduced doses versus high doses with insignificant differences but there was significant increase in fertilization rate in group A versus group B. - Insignificant difference between two groups as regard OHSS. - Significant increase in implantation rate in group A versus group B but there was insignificant difference between two groups as regard clinical pregnancy rate.